YANTAI, China, April 8, 2025 /PRNewswire/ -- On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱®) in patients with generalized myasthenia gravis (gMG) were presented...
Read More Details
Finally We wish PressBee provided you with enough information of ( Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis )
Also on site :
- Fictiv Announces Agreement to Join MISUMI
- Diplomacy wins: Trump blocks Israeli military action against Iran
- A ship full of lifesaving wheat is sailing towards Yemen. When it arrives next month, it may rot or be pillaged